Serial Number
86245232
Owner
Lianyungang Jinkang Pharmaceutical Technology Co. LtdAttorney
Neal MassandFirst Use Date
Feb 1, 2015
Filing Date
Apr 7, 2014
MAGNAFOLATE-C Trademark
Serial Number: 86245232 • Registration: 5266274
Trademark Classes
Owner Contact Info
Jinshan ind. park, Ganyu County,
Jiangsu Province, 222000 , CN
Entity Type: 99
Legal Representation
Correspondence Address
Neal Massand Ni, Wang & Massand, PLLC
8140 Walnut Hill Lane, Ste. 615
Dallas, TX 75231
UNITED STATES
Trademark Details
Filing Date
April 7, 2014
Registration Date
August 15, 2017
First Use Anywhere
February 1, 2015
First Use in Commerce
February 1, 2015
Published for Opposition
March 28, 2017
Goods & Services
Industrial chemicals; chemical preparations for scientific purposes, other than for medical or veterinary use; calcium salts; chemical preparations and raw materials in the nature of L-5- methyl tetrahydrofolate for use in the manufacture pharmaceutical, medical and nutritional products; chemicals for use in industry and science; chemicals for use in the pharmaceutical, nutritional and dietary industries
Medicines for human purposes, namely, L-5- methyl tetrahydrofolate for use as a contraceptive; pharmaceutical preparations for the treatment and prevention of diseases and disorders of the respiratory system, gastrointestinal system, endocrine system, cardiovascular system, nervous system, masculoskeletal system, urinary system, integumentary system and reproductive system; pharmaceutical preparations for treatment of blood disease and disorder; dermatologic pharmaceutical preparations; hormone therapy preparations; pharmaceutical preparations for the treatments of colds, coughs and influenza; pharmaceutical preparations for ophthalmic use; pharmaceutical preparations for treating dandruff, laxatives, analgesics, contraceptives, antiseptics; pharmaceutical preparations for treatment of hypertension; pharmaceutical preparations for treatment of obesity; anti allergic pharmaceutical preparations; pharmaceutical preparations for treatment of gout; anti-inflammatory pharmaceuticals; contraceptive preparations; dietetic foods, namely, folic acid for the treatment of vitamin deficiency; dietetic substances adapted for medical use, namely, folic acid for the treatment of vitamin deficiency; food for babies; nutritional supplements; dietary supplement for animals; antibiotics; vitamin preparations; drugs for medical purposes for the treatment of subacute encephali associated with dementia and vacuolar myelopathy, physiological and pathological vascular and cardiovascular disorders such as premature occlusive arterial diseases, severe vascular diseases in infancy and childhood, progressive arterial stenosis, intermittent claudication, renal vascular hypertension, ischemic cerebrovascular diseases, premature occlusive retinal artery and retinal vein, crebral occlusive arterial diseases, occlusive peripheral arterial diseases, and premature death caused by thromboembolic diseases and/or ischemic heart diseases, autoimmune diseases such as psoriasis, celiac disease, arthritis and inflammatory conditions, megaloblastic anemia caused by folate inficiency, intestinal malabsorption, used as antidote for folic acid antagonists, used for preventing serious toxic effects caused by methotrexate overdose or high-dose therapy, reducing risks of woman miscarriage and/or production of fetuses with neural tube defects, cleft lip and/or palate defects, keeping and/or normalizing homocysteine levels and/or metabolism, changes synthesis of and/or functions and/or variations in dna and rna and changes in synthesis of cells and depression
